Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MALT1 | Q9UDY8 | 3/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MPL | P40238 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31297177 | 0.87 | MAPT (0.54) | P2RY12KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL5314024 | 0.87 | MAPT (0.54) | P2RY12KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL31297176 | 0.87 | MAPT (0.54) | P2RY12KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL29079000 | 0.86 | MPL (0.52) | KDM4ESMN1; SMN2LMNAMALT1NEK2 | |
| SCHEMBL4111137 | 0.85 | P2RY12 (0.48) | P2RY12KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL3690660 | 0.83 | KMT2A (0.49) | P2RY12KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL24213966 | 0.80 | P2RY12 (0.44) | P2RY12KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL28458747 | 0.80 | CNR2 (0.50) | P2RY12KDM4ESMN1; SMN2LMNAMEN1 | |
| SCHEMBL4111253 | 0.79 | CXCR3 (0.49) | P2RY12LMNAMPLCXCR3 | |
| SCHEMBL400589 | 0.79 | TRPV1 (0.49) | P2RY12SMN1; SMN2MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119080739-B | Synthesis method of 5-chloro-6- (4- (ethoxycarbonyl) piperidin-1-yl) nicotinic acid | 深圳智微通科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-119080739-A | Synthesis method of 5-chloro-6- (4- (ethoxycarbonyl) piperidin-1-yl) nicotinic acid | 深圳智微通科技有限公司 | 2024-12-06 | — | — | CN | disclosed |
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | P2RY12 1/4885KDM4E 3376/4885SMN1; SMN2 3557/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | P2RY12 1/4885KDM4E 2316/4885SMN1; SMN2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.